11.95
11.95 (0%)
As of Feb 14, 2025
Tonix Pharmaceuticals Holding Corp. [TNXP]
Source:
Company Overview
Tonix Pharmaceuticals Holding Corp. is a fully-integrated biopharmaceutical company developing and commercializing therapeutics to treat, and vaccines to prevent, diseaseand alleviate suffering.
| Country | United States |
| Headquarters | chatham, new jersey |
| Phone Number | 212-980-9155 |
| Industry | manufacturing |
| CEO | Seth Lederman |
| Website | tonixpharma.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $10.1 |
| Operating Profit | $-136.7 |
| Net Income | $-130 |
| Net Cash | $73.8 |
Profit Ratios
| Gross Margin | $2.3 |
| Operating Margin | -1,354.3 |
| Profit as % of Revenues | -1.8% |
| Profit as % of Assets | -82% |
| Profit as % of Stockholder Equity | -93.2% |
Management Effectiveness
| Return on Equity | -93.2% |
| Return on Assets | -79.8% |
| Turnover Ratio | 6.4% |
| EBITA | $-136.7 |
Balance Sheet and Cash Flow Measures
| Total Assets | $162.9 |
| Total Liabilities | $23.3 |
| Operating Cash Flow | $-60.9 |
| Investing Cash Flow | $-0.1 |
| Financing Cash Flow | $134.9 |
